122 related articles for article (PubMed ID: 15268664)
21. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.
Liu TC; Kirn D
Cancer Res; 2007 Jan; 67(2):429-32. PubMed ID: 17234747
[TBL] [Abstract][Full Text] [Related]
22. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
[TBL] [Abstract][Full Text] [Related]
23. Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma.
Pencavel TD; Wilkinson MJ; Mansfield DC; Khan AA; Seth R; Karapanagiotou EM; Roulstone V; Aguilar RJ; Chen NG; Szalay AA; Hayes AJ; Harrington KJ
Int J Cancer; 2015 Feb; 136(4):965-76. PubMed ID: 24978211
[TBL] [Abstract][Full Text] [Related]
24. Genetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer.
Mohr I
Expert Opin Biol Ther; 2003 Feb; 3(1):113-25. PubMed ID: 12718736
[TBL] [Abstract][Full Text] [Related]
25. Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies.
Autio K; Knuuttila A; Kipar A; Ahonen M; Parviainen S; Diaconu I; Kanerva A; Hakonen T; Vähä-Koskela M; Hemminki A
Vet Comp Oncol; 2016 Dec; 14(4):395-408. PubMed ID: 25302859
[TBL] [Abstract][Full Text] [Related]
26. United virus: the oncolytic tag-team against cancer!
Le Boeuf F; Bell JC
Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
[TBL] [Abstract][Full Text] [Related]
27. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer.
Kirn D
Oncogene; 2000 Dec; 19(56):6660-9. PubMed ID: 11426652
[TBL] [Abstract][Full Text] [Related]
28. Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.
Evgin L; Acuna SA; Tanese de Souza C; Marguerie M; Lemay CG; Ilkow CS; Findlay CS; Falls T; Parato KA; Hanwell D; Goldstein A; Lopez R; Lafrance S; Breitbach CJ; Kirn D; Atkins H; Auer RC; Thurman JM; Stahl GL; Lambris JD; Bell JC; McCart JA
Mol Ther; 2015 Jun; 23(6):1066-1076. PubMed ID: 25807289
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic vaccinia virus for the treatment of cancer.
Guse K; Cerullo V; Hemminki A
Expert Opin Biol Ther; 2011 May; 11(5):595-608. PubMed ID: 21338330
[TBL] [Abstract][Full Text] [Related]
30. Fighting cancer with vaccinia virus: teaching new tricks to an old dog.
Shen Y; Nemunaitis J
Mol Ther; 2005 Feb; 11(2):180-95. PubMed ID: 15668130
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro.
Goncharova EP; Ruzhenkova JS; Petrov IS; Shchelkunov SN; Zenkova MA
J Transl Med; 2016 Aug; 14(1):241. PubMed ID: 27538520
[TBL] [Abstract][Full Text] [Related]
32. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
[TBL] [Abstract][Full Text] [Related]
33. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
34. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.
Thorne SH; Contag CH
Gene Ther; 2008 May; 15(10):753-8. PubMed ID: 18356814
[TBL] [Abstract][Full Text] [Related]
35. Future directions: oncolytic viruses.
You L; He B; Xu Z; McCormick F; Jablons DM
Clin Lung Cancer; 2004 Jan; 5(4):226-30. PubMed ID: 14967074
[TBL] [Abstract][Full Text] [Related]
36. Viruses as nanomedicine for cancer.
Badrinath N; Heo J; Yoo SY
Int J Nanomedicine; 2016; 11():4835-4847. PubMed ID: 27703350
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
[TBL] [Abstract][Full Text] [Related]
38. Live viruses in cancer treatment.
Nemunaitis J
Oncology (Williston Park); 2002 Nov; 16(11):1483-92; discussion 1495-7. PubMed ID: 12469927
[TBL] [Abstract][Full Text] [Related]
39. Replicating adenoviruses in cancer therapy.
Dobbelstein M
Curr Top Microbiol Immunol; 2004; 273():291-334. PubMed ID: 14674605
[TBL] [Abstract][Full Text] [Related]
40. JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
Merrick AE; Ilett EJ; Melcher AA
Curr Opin Investig Drugs; 2009 Dec; 10(12):1372-82. PubMed ID: 19943208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
